Revvity (NYSE:RVTY) Raised to “Hold” at Sanford C. Bernstein

Posted by on Jun 27th, 2026

Revvity (NYSE:RVTY – Get Free Report) was upgraded by analysts at Sanford C. Bernstein to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

A number of other analysts have also recently commented on the company. The Goldman Sachs Group dropped their price objective on Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a research report on Tuesday, April 14th. Wolfe Research initiated coverage on shares of Revvity in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Robert W. Baird set a $117.00 price target on shares of Revvity in a research note on Wednesday, May 6th. Stifel Nicolaus decreased their price target on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $108.33.

View Our Latest Stock Analysis on RVTY

Revvity Price Performance

Shares of NYSE:RVTY opened at $112.98 on Thursday. The business’s fifty day moving average price is $97.46 and its two-hundred day moving average price is $97.75. The stock has a market cap of $12.60 billion, a PE ratio of 54.06, a price-to-earnings-growth ratio of 2.48 and a beta of 1.11. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. Revvity has a one year low of $81.22 and a one year high of $118.30.

Revvity (NYSE:RVTY – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The company had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.07 million. During the same period in the previous year, the firm posted $1.01 earnings per share. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, analysts forecast that Revvity will post 5.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Revvity

Large investors have recently added to or reduced their stakes in the business. Ascentis Independent Advisors acquired a new stake in Revvity in the 1st quarter worth about $29,000. CYBER HORNET ETFs LLC acquired a new position in shares of Revvity during the 2nd quarter valued at about $32,000. Cromwell Holdings LLC lifted its holdings in shares of Revvity by 141.4% during the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after acquiring an additional 198 shares during the period. MUFG Securities EMEA plc purchased a new position in shares of Revvity during the 2nd quarter worth about $34,000. Finally, SJS Investment Consulting Inc. boosted its position in shares of Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after acquiring an additional 521 shares during the last quarter. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

About Revvity

(Get Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

Featured Articles

Analyst Recommendations for Revvity (NYSE:RVTY)

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.